All In Biotech

Drug Trial Radar · NCT06563713

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects

A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Immunogenicity of STSP-0902 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jul 31, 2024

Primary completion

Feb 24, 2025

Study completion Feb 24, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1a, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of STSP-0902.

Conditions

  • Oligozoospermia
  • Asthenozoospermia

Interventions

  • STSP-0902 injectionDrug

    Subjects will receive the administration dose on Day 0 following protocol requirements

  • PlaceboDrug

    Subjects will receive the administration dose on Day 0 following protocol requirements

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment-related adverse events as assessed by CTCAE 5.0Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.